Diametric Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Diametric Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,020	Closed	-$455K	–	698
2026 Q1	$455K	Buy	+1,020	New	+$476K	0.12%	241
2023 Q3	–	Sell	-1,639	Closed	-$577K	–	437
2023 Q2	$577K	Buy	+1,639	New	+$552K	0.26%	106
2020 Q3	–	Sell	-3,736	Closed	-$1.08M	–	184
2020 Q2	$1.08M	Buy	3,736 +72	+2%	+$19.5K	0.83%	42
2020 Q1	$872K	Sell	3,664 -2,789	-43%	-$640K	1.06%	36
2019 Q4	$1.41M	Sell	6,453 -4,064	-39%	-$822K	1.03%	37
2019 Q3	$1.78M	Buy	+10,517	New	+$1.86M	1.47%	22
2019 Q2	–	Sell	-6,722	Closed	-$1.24M	–	153
2019 Q1	$1.24M	Buy	+6,722	New	+$1.24M	0.97%	40

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Diametric Capital's VRTX Position: Q2 2026 in Review

Diametric Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 1,020 shares — an estimated $455K sold.

Diametric Capital first reported a position in VRTX in Q1 2019 and held it in 7 quarters. The position peaked at $1.78M in Q3 2019. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Diametric Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Diametric Capital sold 1,020 Vertex Pharmaceuticals shares in Q2 2026, an estimated $455K.
Diametric Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 7 quarters.
Diametric Capital's Vertex Pharmaceuticals position peaked at $1.78M in Q3 2019.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.